Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
Norihiro KogamePly ChichareonKenneth De WilderKuniaki TakahashiRodrigo ModoloChun-Chin ChangMariusz TomaniakHidenori KomiyamaAlaide ChieffoAntonio ColomboScot GargYves LouvardPeter JüniPhilippe G StegChristian HammPascal VranckxMarco ValgimigliStephan WindeckerHans-Peter StollYoshinobu OnumaLuc JanssensPatrick W J C SerruysPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
After PCI for bifurcation lesions using 1-month of DAPT followed by ticagrelor monotherapy for 23 months did not demonstrate explicit benefit regarding all-cause death or new Q-wave MI as in the overall trial.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- phase iii
- acute myocardial infarction
- open label
- coronary artery disease
- coronary artery bypass grafting
- phase ii
- study protocol
- clinical trial
- combination therapy
- coronary artery bypass
- atrial fibrillation
- endovascular treatment
- heart failure